Dopaminergic D2 and serotoninergic 5HT2 receptors : Functions, interactions and clinical relevance to schizophrenia;Récepteurs dopaminergiques D2 et sérotoninergiques 5HT2 : Fonctions, interactions et conséquences cliniques dans le champ des schizophrénies

Encephale

Volumn 23, Issue SPEC. ISS. 2, 1997, Pages 10-16

  Guise, S ^a   Soubrouillard, C ^a   Blin, O ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

Dopamine; Schizophrenia; Serotonln

Indexed keywords

DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; DOPAMINE RECEPTOR;

BRAIN; DRUG EFFECT; DYSKINESIA; GENETICS; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; REVIEW; SCHIZOPHRENIA; TREATMENT OUTCOME; CONFERENCE PAPER; EXTRAPYRAMIDAL SYNDROME; NEGATIVE SYNDROME;

ANTIPSYCHOTIC AGENTS; BRAIN; DYSKINESIA, DRUG-INDUCED; HUMANS; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME;

EID: 0030956519     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. BLIGH-GLOVER W, JASKIW GE, VRTUNSKI B, UBOGY D, MELTZER HY. 5HT2 receptor antagonists can attenuate sub-maximal haloperidol-induced catalepsy in rats. Schizoph Res, 1995, 15 : 153-4.
2. BERSANI G, GRISPINI A, MARINI S, PASINI A, VALDUCCI M, GIANI N. 5HT2 antagonist ritanserin in neuroleptic-induced parkinsonism : a double-blind comparison with orphenadrine and placebo. Clin Neuropharmacol 1990 ; 13 : 500-6.
3. CASEY DE. Serotoninergic aspects of acute extrapyramjdal syndromes in nonhurnan primates. Psychopharmacol Bull 1989 ; 25 ; 457-9.
4. CASEY DE. Extrapyramidal syndromes : primate models as predictors of clinical response (abstract). Neuropsychopharmacology 1994; 10(3S,part 1):370S.
5. CEULEMANS DL, GELDERS YG, HOPPENBROUWERS ML, REYNTJENS AJ, JANSSEN PA. Effects of serotonjn antagonism in schizophrenia : a pilot study with setoperone. Psychopharmacology (Berl)1G85; 85; 329-32.
6. FUENMAYOR LD, VOGT M. The Influence of cerebral 5-hydroxytryptamine on catalepsy induced by brain amine depleting neuroleptics or by cholinomlmetics. Br J Pharmacol 1979 ; 67 : 309-18.
7. GELDERS YG. Thymosthenic agents, a novel approach in the treatment of schizophrenia, Br J Psychiatry 1989 ; 155 : 33-6.
8. GIES JP, Bases de pharmacologie moléculaire, Paris ; Ellipses, Marketing, 1993.
9. HICKS PB. The effect of serotonic agents on haloperidol-induced catalepsy. Life Sei 1970 ; 47 :1609-15.
10. KAPUR S, REMINGTON G. Serotonin-Dopamlne Interaction and its relevance to schizophrenia. Am J Psychiatry 1996 ; 153 ; 466-76.
11. KOSTQWSKI W, GUMULA W, CZLONKOWSKI A. Reduced cataleptpgenic effects of some neuroleptics In rats with leslonned midbrain raphe and treated with p-chlorophenylalanine. Brain Res 1972 ; 48:443-6.
12. LIEBMAN JM, GERHARDT SC, GERBER R, Effects of 5-HT1A agonists and 5-HT2 antagonists on haloperidol-induced dyskinesia In squirrel monkeys : no evidence for reciprocal 5-HT-DA interaction. Psychopharmacology (Berl) 1989 ; 97 : 456-61.
13. MAJ J, SARNEK J, KLIMEK V, RAWLOW A. On the anticataleptic action of cyproheptadlne. Pharm Biochem Behav 1976 ; 5 : 201-5.
14. REYNTJENS A, GELDERS TG, HOPPENBROUWERS ML, BUSSCHE GV. Thymosthenic effects of ritanserin (R 55667), a centrally acting serotonin-S2 receptor blocker. Drug Development Res 1986; 6 1205-11.
15. SALLER CF, CZUPRYNA MJ, SALAMA AL. 5HT2 receptor blockade by ICI 169,369 and other 5HT2 antagonists modulates the effects of D2 dopamine receptor blockade. J Pharmacol Exp Ther 1990,253:1162-70.
16. SCHWARTZ JC. La neuropharmacologie au présent et au futur. Médecine/Sciences 1995 ; 11 : 375-81,
17. SLIVER H, BLAKER M, WELLER M P, LERER B. Treatment of chronic schizophrenia with cyproheptadine. Biol Psychiatry 1989 ; 25 : 502-4.
18. SLIVER H, NASSAR A. Fluvoxamine improves negative symptoms In treated chronic schizophrenia : an add-on double-blind, placebocontrolled study. Biol Psychiatry 1992 ; 31 : 698-704.
19. SPINA E, DEDOMENICO P, RUELLO C, LONGOBARDO N, GITTOC, ANCIONEM, DIROSA AE, CAPUTI AP. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol 1994 ; 9:281-5.
20. WADENBERG ML, Antagonism by 8-OH-DPAT, but not ritanserin, of catalepsy induced by SCH 23390 in rats. J Neural Trans Gen Sect 1992;89:49-59.